Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145884 · ClinicalTrials.gov registry record · Phase 2
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
A Phase 2 study of Hemangioma, sponsored by Rady Children's Hospital, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02145884 is a Phase 2 study of Hemangioma that has completed, run by Rady Children's Hospital, San Diego. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02145884, a Phase 2 study of Hemangioma, has completed, sponsored by Rady Children's Hospital, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% . Our hypothesis is that timolol will inhibit and possibly reverse growth of appropriate infantile hemangiomas.
Conditions Studied
Interventions
- DRUG timolol maleate 0.5% gel
Study Locations (1)
California
- Pediatric and Adolescent Dermatology, Rady Children's Hospital/University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02145884
The ClinicalTrials.gov registry entry for NCT02145884 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rady Children's Hospital, San Diego, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemangioma appearing as the primary indexed condition, and to 1 intervention - of which timolol maleate 0.5% gel is the first listed.
NCT02145884 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02145884 about?
NCT02145884 is a clinical study titled "Topical Timolol Gel for the Treatment of Infantile Hemangiomas". We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% . Our hypothesis is that timolol will inhibit and possibly reverse growth of appropriate infantile hemangiomas...
What is the current status of trial NCT02145884?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2014-05. Estimated completion is 2016-11.
What conditions does trial NCT02145884 study?
This clinical trial studies the following conditions: Hemangioma.
What interventions are being tested in trial NCT02145884?
The interventions under investigation include: timolol maleate 0.5% gel (DRUG).
Who is sponsoring clinical trial NCT02145884?
This trial is sponsored by Rady Children's Hospital, San Diego, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02145884 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemangioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.